QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN has completed its relocation to the CityLabs 2.0 facility in Manchester, establishing it as a global hub for diagnostics development and Precision Medicine. This expansion supports the company's role in co-developing companion diagnostics with pharmaceutical partners. The site employs around 300 staff and will enhance hybrid and remote work options. QIAGEN has numerous FDA-approved companion diagnostic indications and collaborations with over 25 pharmaceutical firms, reinforcing its commitment to advancing Precision Medicine.
QIAGEN N.V. (NYSE: QGEN) has announced the release of its third quarter and year-to-date results scheduled for November 3, 2021. The report will be available at approximately 21:05 CET / 16:05 EDT. Following this, a conference call will occur on November 4 at 14:30 Frankfurt time where CEO Thierry Bernard and CFO Roland Sackers will discuss the results. Interested parties can access the call via multiple phone numbers, and a replay will be made available after the event.
QIAGEN has launched the QIAreach QuantiFERON-TB test, receiving CE marking to enhance global tuberculosis (TB) detection, particularly in high burden and low-resource areas. This portable device utilizes proven QuantiFERON technology to ensure reliable TB infection testing without needing extensive lab infrastructure. Clinical evaluations show high sensitivity compared to existing standards. Collaborations with distribution partners aim to facilitate affordable access across low and middle-income countries, contributing to global TB elimination targets.
QIAGEN N.V. (NYSE: QGEN) has received a $3.4 million U.S. government contract to enhance production for its NeuMoDx PCR testing systems, supporting ongoing COVID-19 testing efforts. The company aims to increase its output to over 16 million tests per year by March 2022, up from approximately 10 million. This follows a previous $600,000 contract to boost reagent production. The contracts emphasize the critical role of PCR testing in managing the pandemic and underline QIAGEN's commitment to providing essential diagnostic solutions.
QIAGEN has been selected to join the DAX index, effective September 20, 2021, marking a significant achievement as it transitions from MDAX to one of Germany's 40 largest companies by market capitalization. The company, which specializes in molecular testing, aims to deliver over $2 billion in sales in 2021. QIAGEN will also remain in the TecDAX, while reinforcing its commitment to improving health outcomes globally through its innovative Sample to Insight solutions.
QIAGEN N.V. (NYSE: QGEN) has surpassed the milestone of three billion biological samples processed with its consumables kits, highlighting its leadership in molecular testing. The company’s sample preparation technology, considered the gold standard, includes over 500 kits and automated systems. QIAGEN continues to innovate with products related to liquid biopsy and microbiome research. Its growth strategy focuses on solidifying its position as a top-three player in sample technologies, contributing to advancements in molecular diagnostics and next-generation sequencing.
QIAGEN has partnered with GT Molecular to launch a comprehensive wastewater testing solution for COVID-19 surveillance in the U.S. and Canada. This innovative workflow utilizes QIAGEN’s sample-preparation techniques with GT Molecular’s digital PCR assays to deliver results in under 2.5 hours, significantly faster than other systems. The assay complies with CDC guidelines and aims to enhance public health responses by quantifying SARS-CoV-2 levels in wastewater. The solution is now available, and the partnership highlights the growing interest in wastewater epidemiology as a tool for monitoring viral spread.
QIAGEN and OncXerna Therapeutics have entered into a master companion diagnostics agreement to develop a next-generation sequencing (NGS) companion diagnostic for OncXerna’s candidate Navicixizumab, aimed at treating ovarian cancer. The agreement includes a non-exclusive license for the Xerna™ TME panel, which uses RNA-based gene expression data to identify suitable patients. The collaboration aims to advance the Xerna™ TME panel towards regulatory approval, enhancing QIAGEN's position in precision medicine diagnostics and potentially benefiting ovarian cancer patients.
QIAGEN (NYSE: QGEN) has received emergency use authorization from the FDA for its QIAreach® SARS-CoV-2 Antigen Test. This rapid test detects active SARS-CoV-2 infections within 2 to 15 minutes and processes approximately 30 samples per hour, boasting a sensitivity of at least 80% and a specificity of 98%. The test is designed for high-volume testing environments, allowing for simultaneous tests of active and past infections with the QIAreach Anti-SARS-CoV-2 Total Test. This innovation is part of QIAGEN's commitment to enhance COVID-19 testing capabilities.
QIAGEN N.V. (NYSE: QGEN) reported strong financial results for Q2 and the first half of 2021, with a 28% increase in net sales to $567.3 million in Q2. Sales for H1 2021 rose 39% to $1.135 billion. Diluted EPS for Q2 was $0.52, up 22% year-over-year, while adjusted EPS reached $0.67. The company noted reduced demand for COVID-19 testing due to rising vaccination rates but remains optimistic about growth in non-COVID product groups and plans a $100 million share repurchase program.